Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection – a long way to go

References

• Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51:883–890.
   PubMed Web of Science ®Google Scholar
• England MJ, Liverman CT, Schultz AM, et al. Epilepsy across the spectrum: promoting health and understanding. In: Institute of Medicine, editor. Committee on the public health dimensions of the epilepsies. Washington (DC): The National Academies Press; 2012. p. 19–47.
   Google Scholar
• Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155–162.
   PubMed Web of Science ®Google Scholar
• Cardarelli WJ, Smith BJ. The burden of epilepsy to patients and payers. Am J Manag Care. 2010;16:331–336.
   PubMed Web of Science ®Google Scholar
• Pellock JM, Carman WJ, Thyagarajan V, et al. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology. 2012;79:1482–1489.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Concept paper on extrapolation of efficacy and safety in medicine development. EMA/129698/2012. 2012.
   Google Scholar
• Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2015;84:1705–1713.
   PubMed Web of Science ®Google Scholar
• French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252–1260.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Health and Clinical Excellence (NICE). 2012 Jan. 117 p. (Clinical guideline; no. 137).
   Google Scholar
• Kinderformularium. Nederlands Kenniscentrum voor Farmacotherapie bij Kinderen (NKFK). 2016 [cited 2016 May 15]. Available from: https://www.kinderformularium.nl/
   Google Scholar
• Paediatric Formulary Committee. BNF for children. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications; 2016.
   Google Scholar
• Cella M, Knibbe C, de Wildt SN, et al. Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models. Br J Clin Pharmacol. 2012;74:525–535.
   PubMed Web of Science ®Google Scholar
• Cella M, Zhao W, Jacqz-Aigrain E, et al. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol. 2011;72:454–464.6.
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–332.
   PubMed Web of Science ®Google Scholar
• Stagi S, Lasorella S, Piccorossi A, et al. Cessation of epilepsy therapy in children. Expert Rev Neurother. 2016;16:549–559.
   PubMed Web of Science ®Google Scholar
• Park K, Hur Y, Kim H, et al. Initial response to antiepileptic drugs in patients with newly diagnosed epilepsy. J Clin Neurosci. 2014;21:923–926.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000;9:464–468.
   PubMed Web of Science ®Google Scholar
• Sillanpää M, Schmidt D. Predicting antiepileptic drug response in children with epilepsy. Expert Rev Neurother. 2011;11:877–885; quiz 886.
   PubMed Web of Science ®Google Scholar
• Bellanti F, van Wijk RC, Danhof M, et al. Integration of PKPD relationships into benefit-risk analysis. Br J Clin Pharmacol. 2015;80:979–991.
   PubMed Web of Science ®Google Scholar
• EMA Benefit-Risk Methodology Project Team. Benefit-risk methodology project. Work package 4 report: benefit-risk tools and processes. European Medicines Agency [Internet]. 2012;1–20. [cited 2016 Jun 30]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/03/WC500123819.pdf
   Google Scholar
• Holmes E, Plumpton C, Duerden M, et al. New advice on switching antiepileptic drugs might be a false economy. BMJ. 2013;347:f7471.
   PubMed Web of Science ®Google Scholar
• Plumpton CO, Yip VLM, Alfirevic A, et al. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia. 2015;56:556–563.
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet. 2006;45:351–363.
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45:1061–1075.
   PubMed Web of Science ®Google Scholar
• Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52:627–645.
   PubMed Web of Science ®Google Scholar
• Deleu D, Aarons L, Ahmed IA. Population pharmacokinetics of free carbamezipine in adult Omani epileptic patients. Eur J Clin Pharmacol. 2001;57:243–248.
   PubMed Web of Science ®Google Scholar
• Aarons L, Ahmed IA, Deleu D. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. Arch Med Res. 2005;36:49–53.
   PubMed Web of Science ®Google Scholar
• Ueshima S, Aiba T, Makita T, et al. Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children. J Clin Pharm Ther. 2008;33:31–38.
   PubMed Web of Science ®Google Scholar
• Clinckers R, Smolders I, Michotte Y, et al. Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain. Br J Pharmacol. 2008;155:1127–1138.
   PubMed Web of Science ®Google Scholar
• Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47:1253–1284.
   PubMed Web of Science ®Google Scholar
• Friis ML, Christiansen J, Hvidberg EF. Brain concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients. Eur J Clin Pharmacol. 1978;14:47–51.
   PubMedGoogle Scholar
• Rambeck B, Jürgens UH, May TW, et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia. 2006;47:681–694.
   PubMed Web of Science ®Google Scholar
• Christensen J, Højskov CS, Dam M, et al. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit. 2001;23:529–535.
   PubMed Web of Science ®Google Scholar
• Wu C, Honarmand AR, Schnell S, et al. Age‐related changes of normal cerebral and cardiac blood flow in children and adults aged 7 months to 61 years. J Am Heart Assoc. 2016;5:e002657.
   PubMed Web of Science ®Google Scholar
• Koyama H, Sugioka N, Uno A, et al. Age-related alteration of carbamazepine-serum protein binding in man. J Pharm Pharmacol. 1999;51:1009–1014.
   PubMed Web of Science ®Google Scholar
• ter Heine R, van Maarseveen EM, van der Westerlaken MML, et al. The quantitative effect of serum albumin, serum urea, and valproic acid on unbound phenytoin concentrations in children. J Child Neurol. 2013;29:803–810.
   PubMed Web of Science ®Google Scholar
• Lopez-Garcia MA, Feria-Romero IA, Fernando-Serrano H, et al. Genetic polymorphisms associated with antiepileptic metabolism. Front Biosci. 2014;E6:377–386.
   Google Scholar
• Chang Y, Yang L, Zhang M, et al. Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China. Eur J Clin Pharmacol. 2014;70:941–946.
   PubMed Web of Science ®Google Scholar
• Urban TJ, Brown C, Castro R, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008;83:416–421.
   PubMed Web of Science ®Google Scholar
• Piana C, Antunes NDJ, Della Pasqua O. Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs. Expert Opin Drug Metab Toxicol. 2014;10:341–358.
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25–36.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Natsume J, Kidokoro H, et al. The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. Brain Dev. 2016; S0387–7604(16):30021–30023.
   Web of Science ®Google Scholar
• Mikaeloff Y, Rey E, Soufflet C, et al. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. Epilepsia. 2004;45:1448–1452.
   PubMed Web of Science ®Google Scholar
• Bouillon-Pichault M, Jullien V, Bazzoli C, et al. Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4. J Pharmacokinet Pharmacodyn. 2011;38:25–40.
   PubMed Web of Science ®Google Scholar
• Vovk T, Jakovljević MB, Kos MK, et al. A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. Biol Pharm Bull. 2010;33:1176–1182.
   PubMed Web of Science ®Google Scholar
• Glauser TA. Biomarkers for antiepileptic drug response. Biomark Med. 2011;5:635–641.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319.
   PubMed Web of Science ®Google Scholar
• Painter M, Scher M, Stein A, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999;341:485–489.
   PubMed Web of Science ®Google Scholar
• Bittigau P, Sifringer M, Genz K, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A. 2002;99:15089–15094.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12:244–252.
   PubMed Web of Science ®Google Scholar
• Lee H-S, Wang S-Y, Salter DM, et al. The impact of the use of antiepileptic drugs on the growth of children. BMC Pediatr. 2013;13:211.
   PubMed Web of Science ®Google Scholar
• Banach R, Boskovic R, Einarson T, et al. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf. 2010;33:73–79.
   PubMed Web of Science ®Google Scholar
• Farwell J, Lee Y, Hirtz DG, et al. Phenobarbital for febrile seizures—effects on intelligence and on seizure recurrence. N Engl J Med. 1990;322:364–369.
   PubMed Web of Science ®Google Scholar
• Nicoletti A, Sofia V, Vitale G, et al. Natural history and mortality of chronic epilepsy in an untreated population of rural Bolivia: a follow-up after 10 years. Epilepsia. 2009;50:2199–2206.
   PubMed Web of Science ®Google Scholar
• Okuma T, Kumashiro H. Natural history and prognosis of epilepsy: report of a multi-institutional study in Japan. Epilepsia. 1981;22:35–53.
   PubMed Web of Science ®Google Scholar
• Vannest J, Tenney JR, Gelineau-morel R, et al. Cognitive and behavioral outcomes in benign childhood epilepsy with centrotemporal spikes. Epilepsy Behav. 2015;45:85–91.
   PubMed Web of Science ®Google Scholar
• Montouris GD, Wheless JW, Glauser TA. The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome. FDA-Approved Medications. Epilepsia. 2014;55(Suppl 4):10–20.
   Google Scholar
• Schmidt D, Sillanpää M. Evidence-based review on the natural history of the epilepsies. Curr Opin Neurol. 2012;25:159–163.
   PubMed Web of Science ®Google Scholar
• Sloviter RS. The neurobiology of temporal lobe epilepsy: too much information, not enough knowledge. C R Biol. 2005;328:143–153.
   PubMed Web of Science ®Google Scholar
• Bender RA, Baram TZ. Epileptogenesis in the developing brain: what can we learn from animal models? Epilepsia. 2007;48(Suppl 5):2–6.
   PubMed Web of Science ®Google Scholar
• Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther. 2001;90:21–34.
   PubMed Web of Science ®Google Scholar
• Ploeger BA, van der Graaf PH, Danhof M. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet. 2009;24:3–15.
   PubMed Web of Science ®Google Scholar
• Hung -C-C, Chen -C-C, Lin C-J, et al. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008;18:390–402.
   PubMed Web of Science ®Google Scholar
• Weaver DF, Pohlmann-Eden B. Pharmacoresistant epilepsy: unmet needs in solving the puzzle(s). Epilepsia. 2013;54(Suppl 2):80–85.
   PubMed Web of Science ®Google Scholar
• Vega-Hernández A, Felix R. Down-regulation of N-type voltage-activated Ca 2 + channels by gabapentin. Cell Mol Neurobiol. 2002;22:185–190.
   PubMed Web of Science ®Google Scholar
• Byrnes JJ, Miller LG, Greenblatt DJ, et al. Chronic benzodiazepine administration. Chronic benzodiazepine administration. XII. Anticonvulsant cross-tolerance but distinct neurochemical effects of alprazolam and lorazepam. Psychopharmacology (Berl). 1993;11(1):91–95.
   Google Scholar
• Berg AT, Rychlik K. The course of childhood-onset epilepsy over the first two decades: a prospective, longitudinal study. Epilepsia. 2015;56(1):40–48.
   Google Scholar
• Francione S, Liava A, Mai R, et al. Drug-resistant parietal epilepsy: polymorphic ictal semiology does not preclude good post-surgical outcome. Epileptic Disord. 2015;17(1):32–46.
   Google Scholar
• Yamada M, Welty TE. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother. 2012;46:304.
   Web of Science ®Google Scholar
• Crawford P, Feely M, Guberman A, et al. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006;15:165–176.
   PubMed Web of Science ®Google Scholar
• Johannessen C, Beiske G, Baftiu A, et al. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure Eur J Epilepsy. 2015;28:88–91.
   PubMed Web of Science ®Google Scholar
• Marino SE, Birnbaum AK, Leppik IE, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012;91:483–488.
   PubMed Web of Science ®Google Scholar
• Chen C. Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil. Eur J Clin Pharmacol. 2013;69:1809–1817.
   PubMed Web of Science ®Google Scholar
• Krauss GL, Caffo B, Chang Y-T, et al. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol. 2011;70:221–228.
   PubMed Web of Science ®Google Scholar
• Mishra B, Sahoo BL, Mishra M, et al. Design of a controlled release liquid formulation of lamotrigine. Daru. 2011;19:126–137.
   PubMed Web of Science ®Google Scholar
• Jonker DM, Voskuyl RA, Danhof M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia. 2007;48:412–434.
   PubMed Web of Science ®Google Scholar
• Lee JW, Dworetzky B. Rational polytherapy with antiepileptic drugs. Pharmaceuticals. 2010;3:2362–2379.
   Google Scholar
• Stafstrom CE. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol. 2010;23:157–163.
   PubMed Web of Science ®Google Scholar
• Sake J-K, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010;24:1055–1068.
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr Opin Neurol. 2012;25:164–172.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Giorgi FS, et al. Analysis of nocebo effects of antiepileptic drugs across different conditions. J Neurol. 2016;263(7):1274–1279.
   PubMed Web of Science ®Google Scholar
• Faught E. Adherence to antiepilepsy drug therapy. Epilepsy Behav. 2012;25:297–302.
   PubMed Web of Science ®Google Scholar
• Aylward BS, Rausch JR, Modi AC. An examination of 1-year adherence and persistence rates to antiepileptic medication in children with newly diagnosed epilepsy. J Pediatr Psychol. 2015;40(1):66–74.
   Google Scholar
• Smithson WH, Hukins D, Colwell B, et al. Developing a method to identify medicines non-adherence in a community sample of adults with epilepsy. Epilepsy Behav. 2012;24:49–53.
   PubMed Web of Science ®Google Scholar
• De Castro FA, Piana C, Simões BP, et al. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. Br J Clin Pharmacol. 2015;80:618–629.
   PubMed Web of Science ®Google Scholar
• Margineanu DG. Systems biology impact on antiepileptic drug discovery. Epilepsy Res. 2012;98:104–115.
   PubMed Web of Science ®Google Scholar
• Danhof M, Alvan G, Dahl SG, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res. 2005;22:1432–1437.
   PubMed Web of Science ®Google Scholar
• Engel J, Pitkänen A, Loeb JA, et al. Epilepsy biomarkers. Epilepsia. 2013;54(Suppl 4):61–69.
   PubMed Web of Science ®Google Scholar
• Chen X, de Haas S, de Kam M, et al. An overview of the CNS-pharmacodynamic profiles of nonselective and selective GABA agonists. Adv Pharmacol Sci. 2012;2012:134523.
   PubMedGoogle Scholar
• Santen G, van Zwet E, Bettica P, et al. From trial and error to trial simulation III: a framework for interim analysis in efficacy trials with antidepressant drugs. Clin Pharmacol Ther. 2011;89:602–607.
   PubMed Web of Science ®Google Scholar
• Schobben F, Hekster Y, van Zwieten-Boot B. Outcome measures for the assessment of new antiepileptic drugs. Pharm World Sci. 1997;19:223–226.
   PubMedGoogle Scholar
• Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61:275–291.
   PubMed Web of Science ®Google Scholar
• Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008 May 27;70(22 Pt 2):2130–2136.
   PubMed Web of Science ®Google Scholar
• Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006;33:227–279.
   PubMed Web of Science ®Google Scholar
• Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther. 2007;82:21–32.
   PubMed Web of Science ®Google Scholar
• Danhof M, de Jongh J, de Lange ECM, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol. 2007;47:357–400.
   PubMed Web of Science ®Google Scholar
• Lee JY, Garnett CE, Gobburu JVS, et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet. 2011;50:627–635.
   PubMed Web of Science ®Google Scholar
• Knibbe CAJ, Danhof M. Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm. 2011;415:9–14.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care [CG137] [Internet]. 2016. [cited 2016 Jun 30]. Available from: http://www.nice.org.uk/guidance/cg137
   Google Scholar
• Coombes S, Terry JR. The dynamics of neurological disease: integrating computational, experimental and clinical neuroscience. Eur J Neurosci. 2012;36:2118–2120.
   PubMed Web of Science ®Google Scholar
• Deckers CL, Hekster YA, Keyser A, et al. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia. 1997;38:570–575.
   PubMed Web of Science ®Google Scholar
• French JA, Faught E. Rational polytherapy. Epilepsia. 2009;50(Suppl 8):63–68.
   PubMed Web of Science ®Google Scholar
• Milosheska D, Grabnar I, Vovk T. Dried blood spots for monitoring and individualization of antiepileptic drug treatment. Eur J Pharm Sci. 2015;75:25–39.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit. 2013;35:5–29.
   Web of Science ®Google Scholar
• Girgis IG, Nandy P, Nye JS, et al. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to 10 years of age. Epilepsia. 2010;51:1954–1962.
   PubMed Web of Science ®Google Scholar
• Woolf SH. The meaning of translational research and why it matters. JAMA. 2008;299:211–213.
   PubMed Web of Science ®Google Scholar
• Danhof M, de Lange ECM, Della Pasqua OE, et al. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008;29:186–191.
   PubMed Web of Science ®Google Scholar
• Donovan MD, Boylan GB, Murray DM, et al. Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics. Br J Clin Pharmacol. 2016;81:62–77.
   PubMed Web of Science ®Google Scholar
• Brochot A, Zamacona M, Stockis A. Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. Basic Clin Pharmacol Toxicol. 2010;106:256–262.
   PubMed Web of Science ®Google Scholar
• Guillemain I, Kahane P, Depaulis A. Progress in Epileptic Disorders Workshop on AED trials animal models to study aetiopathology of epilepsy: what are the features to model? Epileptic Disord. 2012;14:217–225.
   PubMed Web of Science ®Google Scholar
• Dunne J, Rodriguez WJ, Murphy MD, et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011;128:e1242–9.
   PubMed Web of Science ®Google Scholar
• Chiron C, Dulac O, Pons G. Antiepileptic drug development in children: considerations for a revisited strategy. Drugs. 2008;68:17–25.
   PubMed Web of Science ®Google Scholar
• Kang HE, Lee MG. Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling. Arch Pharm Res. 2011;34:1779–1788.
   PubMed Web of Science ®Google Scholar
• Bonnett L, Smith CT, Smith D, et al. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol. 2012;11:331–340.
   PubMed Web of Science ®Google Scholar
• Ronan L, Alhusaini S, Scanlon C, et al. Widespread cortical morphologic changes in juvenile myoclonic epilepsy: evidence from structural MRI. Epilepsia. 2012;53:651–658.
   PubMed Web of Science ®Google Scholar
• Laufs H, Duncan JS. Electroencephalography/functional MRI in human epilepsy: what it currently can and cannot do. Curr Opin Neurol. 2007;20:417–423.
   PubMed Web of Science ®Google Scholar
• Kim S, Salamon N, Jackson HA, et al. PET imaging in pediatric neuroradiology: current and future applications. Pediatr Radiol. 2010;40:82–96.
   PubMed Web of Science ®Google Scholar
• Wang Y, Bhattaram AV, Jadhav PR, et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004–2006. J Clin Pharmacol. 2008;48:146–156.
   PubMed Web of Science ®Google Scholar
• EFPIA MID3 Workgroup, Marshall SE, Burghaus R, et al. Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol. 2016;5(3):93–122.
   Google Scholar
• Stefan H, Lopes da Silva FH, Löscher W, et al. Epileptogenesis and rational therapeutic strategies. Acta Neurol Scand. 2006;113:139–155.
   PubMed Web of Science ®Google Scholar
• Piana C, Surh L, Furst-Recktenwald S, et al. Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases. J Clin Pharmacol. 2012;52(5):704–716.
   Google Scholar
• Cohen AF. Developing drug prototypes: pharmacology replaces safety and tolerability? Nat Rev Drug Discov. 2010;9:856–865.
   PubMed Web of Science ®Google Scholar
• Harnisch L, Shepard T, Pons G, et al. Modeling and simulation as a tool to bridge efficacy and safety data in special populations. CPT Pharmacometrics Syst Pharmacol. 2013;2:e28.
   PubMedGoogle Scholar
• Jadhav PR, Kern SE. The need for modeling and simulation to design clinical investigations in children. J Clin Pharmacol. 2010;50:121S–129S.
   PubMed Web of Science ®Google Scholar
• Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess. 2005;9(15):1–157.
   PubMed Web of Science ®Google Scholar
• Glauser T, Ben-menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094–1120.
   PubMed Web of Science ®Google Scholar
• Perucca E. Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs. 2008;22:917–938.
   PubMed Web of Science ®Google Scholar
• Perucca E. When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy. Epilepsia. 2010;51:1933–1935.
   PubMed Web of Science ®Google Scholar
• Della Pasqua O. PKPD and disease modeling: concepts and applications to oncology. In: Kimko HH, Peck CC, editors. Clinical trial simulations: applications and trends. New York (NY): Springer; 2011. p. 281–310.
   Google Scholar